More than 100 people attended an open house on Thurs., Jan. 21, for Winship Cancer Institute of Emory University's new community Medical Oncology and Hematology Department at Emory Johns Creek Hospital (EJCH).
Sagar Lonial, MD, an internationally renowned expert in the biology and treatment of patients with multiple myeloma, has been named chair of the Department of Hematology and Medical Oncology within Emory University School of Medicine and Winship Cancer Institute.
Winship Cancer Institute of Emory University has joined all 69 of the nation's top cancer centers in issuing a statement urging increased human papillomavirus (HPV) vaccination for the prevention of cancer.
As part of its new cancer service line, Winship Cancer Institute of Emory University and Emory Healthcare have made two important appointments: Melissa Childress, MBA is the new vice president of cancer services and Kim M. Slusser, MSN, RN, CHPN is the new vice president of cancer nursing.
Aging increases our risk of getting cancer. What if we could control the effects of aging in our bodies in order to prevent or cure cancer? Researcher and physician David S. Yu, MD, PhD, in the Department of Radiation Oncology, is working in his lab to learn more about the gene SIRT2.
Winship Cancer Institute of Emory University has named Mylin A. Torres, MD the new director of the Glenn Family Breast Center effective January 19th.
Emory Johns Creek Hospital is holding an open house on Thurs., Jan. 21, to showcase Winship Cancer Institute of Emory University's new community Medical Oncology and Hematology Department.
Investigators with the Winship Cancer Institute of Emory University and Atlanta Veterans Administration (VA) Medical Center are launching a study to determine if two novel tests developed at Emory can help find kidney cancer at earlier, more treatable, stages.
The cancer center gained national recognition for patient care and for its basic and clinical research initiatives. "It's been an extraordinary year," says Winship Executive Director Walter J. Curran, Jr., MD.
The FDA has approved elotuzumab as part of an innovative immune-based therapy treatment for patients with relapsed multiple myeloma. This is the fourth myeloma drug approved within the last year. All four new agents were tested in clinical trials at Winship Cancer Institute.